176 related articles for article (PubMed ID: 28259941)
21. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
22. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study.
Castaño G; Más R; Gámez R; Fernández L; Illnait J
Angiology; 2004; 55(4):361-71. PubMed ID: 15258682
[TBL] [Abstract][Full Text] [Related]
23. Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese.
Cho KH; Nam HS; Baek SH; Kang DJ; Na H; Komatsu T; Uehara Y
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982259
[TBL] [Abstract][Full Text] [Related]
24. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
Schaefer EJ
Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
[TBL] [Abstract][Full Text] [Related]
25. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
Castaño G; Más R; Fernández L; Illnait J; Mendoza S; Gámez R; Fernández J; Mesa M
Drugs Exp Clin Res; 2005; 31 Suppl():31-44. PubMed ID: 16444910
[TBL] [Abstract][Full Text] [Related]
27. Senescence-related truncation and multimerization of apolipoprotein A-I in high-density lipoprotein with an elevated level of advanced glycated end products and cholesteryl ester transfer activity.
Park KH; Shin DG; Kim JR; Cho KH
J Gerontol A Biol Sci Med Sci; 2010 Jun; 65(6):600-10. PubMed ID: 20421239
[TBL] [Abstract][Full Text] [Related]
28. Cholesteryl ester transfer protein in metabolic syndrome.
Sandhofer A; Kaser S; Ritsch A; Laimer M; Engl J; Paulweber B; Patsch JR; Ebenbichler CF
Obesity (Silver Spring); 2006 May; 14(5):812-8. PubMed ID: 16855190
[TBL] [Abstract][Full Text] [Related]
29. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
30. The lipoprotein lipase S447X and cholesteryl ester transfer protein rs5882 polymorphisms and their relationship with lipid profile in human serum of obese individuals.
Emamian M; Avan A; Pasdar A; Mirhafez SR; Sadeghzadeh M; Moghadam MS; Parizadeh SM; Ferns GA; Ghayour-Mobarhan M
Gene; 2015 Mar; 558(2):195-9. PubMed ID: 25579610
[TBL] [Abstract][Full Text] [Related]
31. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.
Després JP; Ross R; Boka G; Alméras N; Lemieux I;
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):416-23. PubMed ID: 19112166
[TBL] [Abstract][Full Text] [Related]
32. Consumption of high-dose vitamin C (1250 mg per day) enhances functional and structural properties of serum lipoprotein to improve anti-oxidant, anti-atherosclerotic, and anti-aging effects via regulation of anti-inflammatory microRNA.
Kim SM; Lim SM; Yoo JA; Woo MJ; Cho KH
Food Funct; 2015 Nov; 6(11):3604-12. PubMed ID: 26333284
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.
Castaño G; Fernández L; Mas R; Illnait J; Fernández J; Mesa M; Alvarez E; Lezcay M
Int J Clin Pharmacol Res; 2002; 22(2):55-66. PubMed ID: 12503776
[TBL] [Abstract][Full Text] [Related]
34. Cuban Sugar Cane Wax Acid and Policosanol Showed Similar Atheroprotective Effects with Inhibition of LDL Oxidation and Cholesteryl Ester Transfer via Enhancement of High-Density Lipoproteins Functionality.
Cho KH; Bae MA; Kim JR
Cardiovasc Ther; 2019; 2019():8496409. PubMed ID: 31772618
[TBL] [Abstract][Full Text] [Related]
35. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Davidson MH; McKenney JM; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
[TBL] [Abstract][Full Text] [Related]
37. Decreased post-prandial triglyceride response and diminished remnant lipoprotein formation in cholesteryl ester transfer protein (CETP) deficiency.
Inazu A; Nakajima K; Nakano T; Niimi M; Kawashiri MA; Nohara A; Kobayashi J; Mabuchi H
Atherosclerosis; 2008 Feb; 196(2):953-7. PubMed ID: 17399717
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.
Mirkin A; Mas R; Martinto M; Boccanera R; Robertis A; Poudes R; Fuster A; Lastreto E; Yañez M; Irico G; McCook B; Farré A
Int J Clin Pharmacol Res; 2001; 21(1):31-41. PubMed ID: 11708573
[TBL] [Abstract][Full Text] [Related]
39. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency.
Moriyama Y; Okamura T; Inazu A; Doi M; Iso H; Mouri Y; Ishikawa Y; Suzuki H; Iida M; Koizumi J; Mabuchi H; Komachi Y
Prev Med; 1998; 27(5 Pt 1):659-67. PubMed ID: 9808796
[TBL] [Abstract][Full Text] [Related]
40. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
Boekholdt SM; Kuivenhoven JA; Wareham NJ; Peters RJ; Jukema JW; Luben R; Bingham SA; Day NE; Kastelein JJ; Khaw KT
Circulation; 2004 Sep; 110(11):1418-23. PubMed ID: 15337694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
